Adults ignore glaucoma risk

Article

Results of an international survey have found that the majority of people aged over 40 years of age do not attend eye examinations.

Results of an international survey have found that the majority of people aged over 40 years of age do not attend eye examinations.

The survey was launched as part of the All Eyes on Glaucoma campaign, a global initiative sponsored by Pfizer Ophthalmics and supported by the World Glaucoma Association and the World Glaucoma Patient Association, which aims to educate people on how to recognize the risk of developing glaucoma.

A total of 4,352 people were surveyed in Australia, Brazil, Germany, Japan, Spain, the UK and the US. Less than half of those had undergone an eye pressure check and just two fifths had visited an eye specialist in the last year.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.